Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has revealed groundbreaking clinical data on its novel therapeutic agent, PRT3789, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona. …
Prelude Therapeutics Unveils Promising Data on PRT3789 at ESMO Congress 2024 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, reported its financial results for the second quarter ending June 30, 2024. The company also provided significant …
Prelude Therapeutics Reports Q2 Financial Results and Key Clinical Developments Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced a collaboration with Merck to evaluate a new cancer treatment. The Phase 2 clinical trial will test Prelude’s investigational drug, …
Prelude Therapeutics Joins Forces with Merck for Cancer Treatment Trial Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) recently shared its first quarter financial results. But even more newsworthy is the ongoing progress and future milestones slated for its novel …
Prelude Therapeutics Progresses in Cutting-Edge Cancer Treatment Development Read More